期刊
EXPERT OPINION ON INVESTIGATIONAL DRUGS
卷 17, 期 3, 页码 413-422出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.3.413
关键词
acquired immune deficiency syndrome; AIDS; antiretroviral therapy; HIV-1; integrase inhibitor; raltegravir
Background: The need to develop antiretroviral agents with novel mechanisms of action persists for the treatment of both antiretroviral-experienced and antiretroviral-naive patients with HIV/AIDS. This is mandated, in part, by the perpetual advent of antiretroviral-resistant HIV-1 strains. Raltegravir has been shown to specifically inhibit the essential, HIV-1-encoded, integrase enzyme. As a result, this agent represents a promising chemotherapeutic agent for the treatment of HIV/AIDS. Objective: To form an evidence-based determination of the clinical efficacy, pharmacokinetics and safety profile of raltegravir. Method: We discuss available peer-reviewed publications, preliminary data presented in abstract from relevant scientific meetings and data available from the US Food and Drug Administration (FDA). Results/conclusion: Current evidence strongly supports raltegravir use in highly active antiretroviral therapy (HAART) regimens constructed to treat patients failing current therapies with multidrug-resistant HIV-1. Additional data are needed to determine its role in the treatment of less advanced patients. Issue surrounding long-term adverse effects and genetic barriers to raltegravir resistance will be critical in determining the potential of this agent.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据